Form 4: Actuate Therapeutics Director Granted 15,000 Stock Options

Actuate Therapeutics, Inc. Director Dan Zabrowski was granted 15,000 stock options with an exercise price of $10.1, vesting on the anniversary of the grant date.

Summary

• Dan Zabrowski, a Director of Actuate Therapeutics, Inc. (ACTU), was granted 15,000 stock options.
• The transaction date for this grant was May 22, 2025.
• The exercise price for these stock options is $10.1 per share.
• The options are scheduled to vest in full on the anniversary of the grant date, which is May 22, 2025.
• The expiration date for these stock options is May 22, 2035.
• Following this transaction, Mr. Zabrowski beneficially owns 15,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The sentiment is mildly positive as the grant of stock options to a director is a common practice that aligns management's interests with shareholders. It indicates ongoing compensation and retention efforts for key personnel. However, as a routine Form 4, it's largely neutral in terms of significant market impact.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, incentivizing long-term performance.
• The options vest in full on the anniversary of the grant date, providing a clear vesting schedule.

Future Outlook

The document primarily reports a past transaction (grant of options) and provides future dates for vesting and expiration of these options. It does not contain broader forward-looking statements or guidance regarding company performance or strategy.

Industry Context

This Form 4 filing is a standard regulatory disclosure for insider transactions, specifically the grant of equity compensation to a director. Such grants are common practice across industries to incentivize and retain key personnel, aligning their financial interests with the company's performance.

Corporate Governance

Related Party Transactions

• The grant of 15,000 stock options to Dan Zabrowski, a Director of Actuate Therapeutics, Inc., constitutes a related party transaction as it involves compensation provided to a member of the company's board.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also potential for increased shareholder value due to incentivized director performance.
• Director (Dan Zabrowski): Receives equity-based compensation, aligning personal financial interests with company performance.

Next Steps

• The stock options will vest in full on May 22, 2025.
• The stock options will expire on May 22, 2035.

Key Dates

Keywords

Actuate Therapeutics, ACTU, Stock Options, Director Compensation, Form 4, Beneficial Ownership, Insider Transaction